Latest in Research

  • 6 Reasons to Attend JDRF’s Virtual TypeOneNation Summit

    September 2, 2020

    Plus, previous TypeOneNation Summit attendees share their experiences and tell us why they keep coming back.  

  • Cell Therapy Approaches Moving Along the Pipeline

    August 13, 2020

    Beta cell replacement therapies for type 1 diabetes (T1D) have made significant advances in just the past 10 years. We now have...

  • JDRF: Accelerating Mission and Becoming More Volunteer Powered

    July 29, 2020

    JDRF's bold vision for the future outlines strategies to drive greater impact to unlock cures and drive research that improves the lives of people with type one diabetes (T1D).

  • JDRF’s One Night: The Power of Us Is Unstoppable

    June 23, 2020

    One Night. One Community. One Purpose: to show the world the undeniable power of people living with T1D.

  • Tandem Control-IQ—Now Authorized For Children

    June 17, 2020

    Tandem Diabetes announced FDA clearance of an expanded pediatric indication for the Tandem t:slim X2™ insulin pump with Control-IQ™ technology in children ages six and older.

  • University of Michigan Establishes Elizabeth Weiser Caswell Diabetes Institute

    June 15, 2020

    Named for JDRF Research Committee member Elizabeth Caswell, Institute will support diabetes research and development of life-changing diabetes therapies.

  • JDRF Top Advances Over the Past Year

    June 9, 2020

    At JDRF, we are committed to funding the development of new therapies to keep people with type 1 diabetes (T1D) healthier, longer,...

  • From the Archives: Mapping Directions for Diabetes Research

    June 3, 2020

    A historical account about a past initiative that would help pave the way for JDRF’s future approach to identifying research priorities.

  • Dr. Jane Buckner Discusses Hydroxychloroquine T1D Prevention Study

    May 28, 2020

    Details about the TrialNet study, including why Hydroxychloroquine, and the status of subject participation.